China Universal Asset Management Co. Ltd. Has $132,000 Stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA)

China Universal Asset Management Co. Ltd. grew its stake in Olema Pharmaceuticals, Inc. (NASDAQ:OLMA) by 67.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,014 shares of the company’s stock after buying an additional 4,442 shares during the period. China Universal Asset Management Co. Ltd.’s holdings in Olema Pharmaceuticals were worth $132,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. Point72 Asset Management L.P. bought a new position in Olema Pharmaceuticals during the second quarter worth $34,753,000. Janus Henderson Group PLC increased its holdings in shares of Olema Pharmaceuticals by 74.5% during the 1st quarter. Janus Henderson Group PLC now owns 1,221,662 shares of the company’s stock worth $13,817,000 after purchasing an additional 521,562 shares during the period. Candriam S.C.A. raised its position in shares of Olema Pharmaceuticals by 199.9% during the second quarter. Candriam S.C.A. now owns 1,058,673 shares of the company’s stock valued at $11,454,000 after buying an additional 705,655 shares during the last quarter. Great Point Partners LLC acquired a new position in shares of Olema Pharmaceuticals during the second quarter valued at about $8,622,000. Finally, Victory Capital Management Inc. lifted its stake in shares of Olema Pharmaceuticals by 26.9% in the second quarter. Victory Capital Management Inc. now owns 774,792 shares of the company’s stock valued at $8,383,000 after buying an additional 164,143 shares during the period. Institutional investors own 91.78% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. JPMorgan Chase & Co. decreased their price objective on Olema Pharmaceuticals from $33.00 to $31.00 and set an “overweight” rating on the stock in a report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Olema Pharmaceuticals in a research note on Thursday, October 24th. Finally, Oppenheimer restated an “outperform” rating and issued a $30.00 price objective on shares of Olema Pharmaceuticals in a research note on Wednesday, August 7th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has an average rating of “Buy” and an average price target of $27.00.

Olema Pharmaceuticals Stock Performance

OLMA opened at $11.53 on Friday. The firm’s fifty day moving average is $12.01 and its two-hundred day moving average is $11.85. The firm has a market cap of $660.28 million, a PE ratio of -5.57 and a beta of 2.02. Olema Pharmaceuticals, Inc. has a twelve month low of $8.51 and a twelve month high of $17.79.

Olema Pharmaceuticals (NASDAQ:OLMA) last issued its quarterly earnings data on Tuesday, August 6th. The company reported ($0.54) EPS for the quarter, hitting the consensus estimate of ($0.54). Equities analysts forecast that Olema Pharmaceuticals, Inc. will post -1.51 EPS for the current fiscal year.

About Olema Pharmaceuticals

Olema Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer.